Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,840 | 0,890 | 12:39 |
Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen |
SUSANNAH CONSTANTINE, 63, CHOOSES THE NEW ALMA HARMONY BIO-BOOST FOR MID-LIFE SKIN CONFIDENCE | *The Next Generation Collagen Laser Facial for glowing, smoother, firmer skin*
The author, podcaster and TV personality Susannah Constantine, 63, opens up about confidence, ageing, and... ► Artikel lesen |
Pre-market Movers: Alti Global, CXApp, PAM Transportation Services, Harmony Biosciences, iCoreConnect | ROME (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 09.15 A.M. ET).In the Green CXApp Inc (CXAI) is up over 37% at $1.11.
PAM Transportation... ► Artikel lesen |
Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update | Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial... ► Artikel lesen |
Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen |
Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update | Sanofi to advance Kymera's next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474 In preclinical testing, KT-485 demonstrated increased... ► Artikel lesen |